MTOR and leukemia: In combination with other agents, the blockage of PI3K/mTOR pathway in pancreatic cancer was able to eliminate pancreatic CSCs and leukemia stem cells, demonstrating the anti-CSC efficacy of inhibiting the PI3K/mTOR pathway [21], [22].